source
- Scribe targets $96 million from Nasdaq IPO as Scholar Rock awaits site classification for apitegromabScribe, a gene-editing biotech, announced plans for a Nasdaq initial public offering that could raise roughly $96 million. The company said it would price the shares at $14 each, which is the midp…
- Biogen reports mixed Alzheimer’s trial results as industry sees new startup launchesBiogen released data from its Alzheimer’s program that showed mixed outcomes, indicating some signals but also setbacks. The weekly newsletter also highlighted the launch of two new biotech startu…